GSK-208136/017 (MeMuRu-OKA-017)

Study to assess immunogenicity, reactogenicity and safety of a 2nd dose of GlaxoSmithKline Biologicals’ measles-mumps-rubella-varicella (MeMuRu-OKA) vaccine given in healthy children of 5 to 6 years of age
Combined Measles, Mumps, Rubella, Varicella Vaccine
208136/017 (MeMuRu-OKA-017)
Measles; Mumps; Rubella; Varicella
Phase 2
An annotated case report form is not available for this study. A blank case report form will be provided.A link to and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
September 2015